<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Mayo Clinic Research news and Discovery's Edge</title><link>/rss/research-news</link><description>Find news related to research at Mayo Clinic.</description><language>en-US</language><item><title>3D-bioprinted human skin model expands options for preclinical research</title><description>In a laboratory at Mayo Clinic, a machine that looks strikingly similar to a desktop printer is quietly reshaping the future of dermatology. Instead of ink, it dispenses living human cells. Instead of paper, it builds tissue — layer by layer — replicating one of the body's most complex organs: skin. For Saranya Wyles, M.D., Ph.D., a dermatologist and researcher at Mayo Clinic, the journey into 3D bioprinting began not with an ambitious plan to reinvent tissue engineering, but with a practical problem. Her team needed a better way to test new therapies.</description><link>https://newsnetwork.mayoclinic.org/?p=413103</link><pubDate>Tuesday, May 5, 2026</pubDate></item><item><title>Improving how multiple myeloma is understood and treated</title><description>Getty Images ROCHESTER, Minn. — Research from Mayo Clinic is helping refine how multiple myeloma is diagnosed and treated, with findings that support more personalized therapies and identify promising immunotherapy strategies for aggressive forms of the disease. The research led by Sikander Ailawadhi, M.D., Shaji Kumar, M.D., Akhilesh Pandey, M.D., Ph.D., and Richard Kandasamy, Ph.D. in the Mayo Clinic Comprehensive Cancer Center, focuses on tailoring treatment based on disease biology and improving outcomes for patients&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=414127</link><pubDate>Monday, May 4, 2026</pubDate></item><item><title>Mayo Clinic study finds remote monitoring may detect early complications, reduce burden for lung transplant patients</title><description>ROCHESTER, Minn. — In a study published in the Journal of Heart and Lung Transplantation Open (JHLT Open), Mayo Clinic researchers found that remote patient monitoring (RPM) is a feasible and effective way to detect early health changes and support care decisions for lung transplant recipients during their first year after discharge from the hospital. Lung transplant recipients require intensive, ongoing monitoring after transplant to detect complications such as rejection or infection. "Many of these&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413982</link><pubDate>Wednesday, April 29, 2026</pubDate></item><item><title>Mayo Clinic AI helps specialists detect pancreatic cancer up to 3 years before diagnosis in landmark validation study</title><description>Animated illustration shows the progression of pancreatic cancer as abnormal cells grow and spread within the pancreas. Getty Images. ROCHESTER, Minn. — A Mayo Clinic-developed artificial intelligence (AI) model can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible. The findings, published in Gut, mark a milestone in Mayo Clinic's&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=412968</link><pubDate>Wednesday, April 29, 2026</pubDate></item><item><title>Blood test shows promise for detecting testicular cancer when standard markers miss</title><description>ROCHESTER, Minn. — Mayo Clinic researchers have developed a blood-based method that may help detect germ cell tumors, the most common type of testicular cancer, including cases that do not show up on standard blood tests, according to a study published in Nature Communications. Testicular cancer most often affects adolescents and young adults, and it is highly treatable, especially when found early. However, diagnosis can be challenging when tumors do not produce enough of the&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413955</link><pubDate>Tuesday, April 28, 2026</pubDate></item><item><title>Mayo Clinic study finds bariatric surgery associated with greater long-term heart risk reduction than weight-loss medications </title><description>ROCHESTER, Minn. — A Mayo Clinic study found that both metabolic and bariatric surgery and GLP-1 medications improve cardiovascular health in people with obesity, but surgery was associated with significantly greater reductions in long-term cardiovascular risk. The findings were published in Annals of Surgery. The study is a direct comparison of two leading obesity treatments, evaluating how each approach affects overall risk of cardiovascular disease. Wissam Ghusn, M.D. "Both treatments are effective, but surgery appears&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413939</link><pubDate>Tuesday, April 28, 2026</pubDate></item><item><title>At what age does Alzheimer's disease begin? Mayo Clinic study points to changes decades before symptoms</title><description>Getty Images ROCHESTER, Minn. — Subtle biological changes linked to Alzheimer’s disease may begin as early as the late 50s — decades before memory loss or other symptoms appear — according to new research from Mayo Clinic. The study, published in Alzheimer’s &amp;amp; Dementia: The Journal of the Alzheimer’s Association, maps when key brain and blood-based changes tend to accelerate across the lifespan, offering new insight into when detection and prevention efforts could have the&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413909</link><pubDate>Tuesday, April 28, 2026</pubDate></item><item><title>Noninvasive proton beam therapy may help treat dangerous heart rhythm disorder</title><description>ROCHESTER, Minn. — Mayo Clinic researchers report that a highly targeted, noninvasive form of radiation therapy reduced episodes of a life-threatening heart rhythm disorder by nearly 80% in a first-in-human early feasibility study of patients with few remaining treatment options.   The findings, presented as late-breaking research at the Heart Rhythm Society conference on April 26 and published in the Heart Rhythm Journal, suggest proton beam therapy could offer a new approach for patients with&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413839</link><pubDate>Monday, April 27, 2026</pubDate></item><item><title>Mayo Clinic builds on breakthrough discoveries to advance care for ALS and FTD</title><description>Momentum is growing in the fight against amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two devastating neurological diseases now understood to be closely connected. At Mayo Clinic, researchers and clinicians are turning scientific breakthroughs into progress for patients and their families. Watch: Dr. Bjorn Oskarsson explains work of ALS researchers https://www.youtube.com/watch?v=Qti5aHBFKls Journalists: Broadcast-quality soundbites are available for download at the end of this post.&amp;nbsp;Please courtesy: "Mayo Clinic." ALS, also known as motor neuron disease&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413819</link><pubDate>Monday, April 27, 2026</pubDate></item><item><title>AI, robotics and motion-preserving implants expand spine surgery options for patients</title><description>Dr. Ahmad Nassr displays a 3D-printed model. Mayo Clinic orthopedic surgeon describes advances in care for common back, neck problems ROCHESTER, Minn. — People worldwide seek medical care for back and neck pain, which can interfere with sleep, mobility and daily life. For individuals who need surgery for spinal conditions, advances in robotics, artificial intelligence (AI) and motion-preserving implants are expanding treatment options and allowing for more personalized treatment, according to Ahmad Nassr, M.D., orthopedic&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413525</link><pubDate>Thursday, April 23, 2026</pubDate></item><item><title>Mayo Clinic research supports targeted therapy to manage kidney complications, potentially enabling continuation of lifesaving immunotherapy</title><description>Getty Images ROCHESTER, Minn. — Immune checkpoint inhibitors (ICIs) have transformed treatment for many types of cancer. In some patients, however, ICIs are associated with immune-related complications that can affect the kidneys. These complications sometimes require care teams to pause or discontinue lifesaving treatment. A study led by Sandra Herrmann, M.D., an onconephrologist and researcher at Mayo Clinic, helps clarify how immune-related kidney inflammation develops and provides preclinical evidence supporting a targeted approach that could&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413614</link><pubDate>Wednesday, April 22, 2026</pubDate></item><item><title>How innovation is shaping the future of transplant care (VIDEO)</title><description>Michelle Nguyen, M.D., tansplant surgeon PHOENIX — This National Donate Life Month, Mayo Clinic is highlighting how innovation is shaping the future of transplant care. "Over the last 50 years, transplant safety and outcomes have improved dramatically, making it a successful treatment for many patients. Since joining Mayo Clinic in 1976, I've seen how teamwork, research and high-volume expertise have driven advances," says Sylvester Sterioff, M.D., retired transplant surgeon. Mayo Clinic performed its first transplant&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413560</link><pubDate>Wednesday, April 22, 2026</pubDate></item><item><title>Mayo Clinic researcher awarded Breakthrough Prize for ALS-dementia gene discovery</title><description>Rosa Rademakers, Ph.D., Photo courtesy: Ine Dehandschutter, VIB Center for Molecular Neurology, University of Antwerp JACKSONVILLE, Fla. — Rosa Rademakers, Ph.D., a neurogeneticist whose work at Mayo Clinic led to a landmark finding in neurodegenerative disease, has been awarded the 2026 Breakthrough Prize in Life Sciences for the discovery of the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which charted the path for new mechanistic studies of these diseases.&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413099</link><pubDate>Sunday, April 19, 2026</pubDate></item><item><title>Mayo Clinic researchers outline a new era of personalized care for patients with meningioma</title><description>ROCHESTER, Minn. — A comprehensive new review led by Mayo Clinic is helping shape how clinicians diagnose and treat meningioma, the most common primary brain tumor, with a focus on personalized, patient-centered care and the latest advances in precision oncology. Published in Nature Reviews Clinical Oncology, the review brings together global expertise to map the future of meningioma care, highlighting innovations that aim to improve outcomes and quality of life for patients. Gelareh Zadeh, M.D.,&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413501</link><pubDate>Friday, April 17, 2026</pubDate></item><item><title>Mayo Clinic researchers present advances in immunotherapy, biomarkers and tumor biology at AACR 2026 </title><description>ROCHESTER, Minn. — Mayo Clinic Comprehensive Cancer Center scientists, physicians and trainees will present nearly 60 studies on emerging cancer therapies, diagnostics and prevention strategies at the 2026 American Association for Cancer Research (AACR) Annual Meeting, April 17–22 at the San Diego Convention Center. The meeting is a premier forum for the global cancer research community to share the latest advances in cancer science and medicine. &amp;nbsp; Mayo Clinic presentations will highlight advances in tumor&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413289</link><pubDate>Thursday, April 16, 2026</pubDate></item><item><title>Using technology to treat Parkinson's: Inside neurodegenerative movement disorders (VIDEO)</title><description>Sean Pittock, M.D. Neurodegenerative movement disorders arise when the brain's complex network of neural circuits begins to break down, disrupting the systems that control movement, cognition, speech and behavior. Conditions like Parkinson's disease often develop silently over years, with symptoms appearing only after significant neurological damage has already occurred. As a result, researchers are increasingly focused on earlier detection and new ways to repair or modulate these damaged circuits using advanced technologies. Sean Pittock, M.D., is a&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413265</link><pubDate>Thursday, April 16, 2026</pubDate></item><item><title>New awards aim to accelerate regenerative therapies for Minnesotans</title><description>Regenerative Medicine Minnesota (RMM) has awarded funding to 10 high-impact projects aimed at accelerating the development of breakthrough therapies that restore, replace or regenerate damaged cells, tissues and organs. Co-led by the University of Minnesota and Mayo Clinic, Regenerative Medicine Minnesota brings together the state's leading research institutions to advance regenerative medicine and improve patient care. The 2026 awards are advancing innovative therapeutic approaches alongside critical tools and technologies that improve how these therapies are&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=413149</link><pubDate>Wednesday, April 15, 2026</pubDate></item><item><title>New Mayo Clinic technique identifies proteins that trigger immune responses in transplants, implants</title><description>Mayo Clinic researchers have developed a new way to identify which proteins are most likely to trigger an immune response — a finding that could help improve transplant care, regenerative biotherapeutics and other areas of medicine where the immune system plays a critical role.</description><link>https://newsnetwork.mayoclinic.org/?p=412649</link><pubDate>Monday, April 6, 2026</pubDate></item><item><title>Mayo Clinic experimental dual-drug nanotherapy crosses the blood-brain barrier and improved survival in preclinical glioblastoma models</title><description>JACKSONVILLE, Fla. —&amp;nbsp;Mayo Clinic&amp;nbsp;researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, according to a&amp;nbsp;study&amp;nbsp;published in Nature Communications Medicine. The strategy extended survival in preclinical models of&amp;nbsp;glioblastoma, the most aggressive form of brain cancer. The nanotechnology-based approach packages two existing cancer drugs into tiny particles engineered to cross the brain's protective blood-brain barrier and target tumor cells. In preclinical models using patient-derived tissue, combining the treatment with radiation more than&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=412828</link><pubDate>Monday, April 6, 2026</pubDate></item><item><title>Mayo Clinic study finds wearable data may help predict patient engagement in remote COPD rehabilitation</title><description>ROCHESTER, Minn. — Sleep data captured with a wearable device could help clinicians better tailor care by identifying patients with chronic obstructive pulmonary disease (COPD) who may need additional support to participate in pulmonary rehabilitation, according to new research published in Mayo Clinic Proceedings: Digital Health. COPD is a long-term lung disease that makes it hard to breathe after airways become inflamed and narrowed and mucus builds up. COPD can also make sleeping more difficult,&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=412394</link><pubDate>Thursday, March 26, 2026</pubDate></item></channel></rss>